Phathom Q3 revenue $49.5M, up 25% QoQ; net loss $30M; FY guidance raised to $170-175M

Phathom Pharmaceuticals, Inc.

2025-Q3 EPS reported -$2.76 revenue$117,526,000

Net revenue of $49.5M in Q3 2025, up 25% from Q2 and from $16.4M in Q3 2024.
Net loss narrowed to $30.0M from $85.6M in Q3 2024; non-GAAP adjusted net loss $11.2M.
Full-year 2025 revenue guidance raised to $170-175M; expects operating profitability in 2026.
Over 790,000 cumulative VOQUEZNA prescriptions filled; Q3 filled prescriptions up 28% QoQ.
Appointed Sanjeev Narula as CFO/Chief Business Officer and Nancy Phelan as SVP Marketing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.